Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype

Hepatology

Volumn 25, Issue 3, 1997, Pages 735-739

  Mihm, Sabine ^a   Fayyazi, Afshin ^b   Hartmann, Heinz ^a   Ramadori, Giuliano ^a,b  

^a Sect Gastroenterol Endocrinol   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILE DUCT INJURY; CONTROLLED STUDY; FATTY LIVER; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS TYPING;

ADULT; AGED; ALANINE TRANSAMINASE; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; MALE; MIDDLE AGED;

EID: 0031055840     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250340     Document Type: Article

References (14)

1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
2. Wejstal R. Immune-mediated liver damage in chronic hepatitis C. Scand J Gastroenterol 1995;30:609-613.
3. Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC Jr, Balart LA, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. Gastroenterology 1993;104:595-603.
4. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. HEPATOLOGY 1992;15:567-571.
5. Fischer H-P, Willsch E, Bierhoff E, Pfeifer U. Histopathologic findings in chronic hepatitis C. J Hepatol 1996;24(suppl 2):35-42.
6. Simmonds P. Variability of hepatitis C virus. HEPATOLOGY 1995;21:570-583.
7. Han JH, Houghton M. Group specific sequences and conserved secondary structures at the 3' end of HCV genome and its implication for viral replication. Nucleic Acids Res 1992;20:3520.
8. Tsukiyama Kohara K, Iizuka N, Kohara M, Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J Virol 1992;66:1476-1483.
9. Onto E, Mizokami M, Mizoguchi N, Ohba K-I, Tohnai M, Yamanaka H, Oguri T, et al. Hepatitis C virus serotype II responds more favorably to interferon-α therapy. J Hepatol 1994;21:130-132.
10. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994;39:977-982.
11. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. HEPATOLOGY 1994;19:1088-1094.
12. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. HEPATOLOGY 1995;21:291-297.
13. Hino K, Okuda M, Konishi T, Ishiko H, Okita K. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-α therapy. Dig Dis Sci 1995;40:14-20.
14. Mihm S, Hartmann H, Fayyazi A, Ramadori G. Preferential virological response to interferon-α2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low γ-GT/ALT ratio. Dig Dis Sci 1996;41:1256-1264.